Liraglutide and Exenatide in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

<b>Background/Objective:</b> Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit neuroprotective properties in preclinical models of Alzheimer’s disease (AD), reducing amyloid accumulation, neuroinflammation, and insulin resistance within the brain. However, clinical evidence regarding the...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Paula Santos, Alberto Souza Sá Filho, Vicente Aprigliano, Amanda G. Duarte, Natã Alegransi Ribeiro, Katia Marques Lombardo, James Oluwagbamigbe Fajemiroye, Artur Prediger Buchholz, Victor Renault Vaz, Gaspar R. Chiappa
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2026-01-01
Serier:	Pharmaceutics
Fag:	GLP-1 receptor agonists liraglutide exenatide Alzheimer’s disease mild cognitive impairment cognition
Online adgang:	https://www.mdpi.com/1999-4923/18/1/69
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!